MA37649B1 - Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées - Google Patents

Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées

Info

Publication number
MA37649B1
MA37649B1 MA37649A MA37649A MA37649B1 MA 37649 B1 MA37649 B1 MA 37649B1 MA 37649 A MA37649 A MA 37649A MA 37649 A MA37649 A MA 37649A MA 37649 B1 MA37649 B1 MA 37649B1
Authority
MA
Morocco
Prior art keywords
producing hydroxylated
compounds
cyclopenta
cyclopentylpyrimidine compounds
hydroxylated cyclopentylpyrimidine
Prior art date
Application number
MA37649A
Other languages
English (en)
French (fr)
Other versions
MA37649A1 (fr
Inventor
Travis Remarchuk
Jonathan W Lane
Sagar Shakya
Keith L Spencer
Peter J Stengel
Original Assignee
Array Biopharma Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc
Publication of MA37649A1 publication Critical patent/MA37649A1/fr
Publication of MA37649B1 publication Critical patent/MA37649B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA37649A 2012-05-17 2013-05-17 Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées MA37649B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648421P 2012-05-17 2012-05-17
US201361785281P 2013-03-14 2013-03-14
PCT/US2013/041624 WO2013173736A1 (en) 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds

Publications (2)

Publication Number Publication Date
MA37649A1 MA37649A1 (fr) 2016-06-30
MA37649B1 true MA37649B1 (fr) 2017-03-31

Family

ID=48534507

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37649A MA37649B1 (fr) 2012-05-17 2013-05-17 Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées

Country Status (18)

Country Link
US (1) US9309204B2 (enExample)
EP (1) EP2861583B1 (enExample)
JP (1) JP6214636B2 (enExample)
KR (1) KR20150020211A (enExample)
CN (1) CN104487430B (enExample)
AU (1) AU2013262568B2 (enExample)
BR (1) BR112014028570A2 (enExample)
CA (1) CA2873653A1 (enExample)
DK (1) DK2861583T3 (enExample)
ES (1) ES2588878T3 (enExample)
IL (1) IL235714A0 (enExample)
MA (1) MA37649B1 (enExample)
MX (1) MX2014013865A (enExample)
PL (1) PL2861583T3 (enExample)
RU (1) RU2014151017A (enExample)
SG (1) SG11201407613RA (enExample)
SI (1) SI2861583T1 (enExample)
WO (1) WO2013173736A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2858989T3 (da) 2012-05-17 2020-06-02 Genentech Inc Amorf form af en AKT-hæmmende pyrimidinyl-cyclopentan-forbindelse, sammensætninger deraf og fremgangsmåder dertil
KR102123131B1 (ko) 2012-05-17 2020-06-15 제넨테크, 인크. 하이드록실화 사이클로펜타피리미딘 화합물 및 이의 염의 제조 방법
CN104520263B (zh) 2012-05-17 2016-11-09 基因泰克公司 制备氨基酸化合物的方法
DK2861582T3 (en) 2012-05-17 2016-08-22 Array Biopharma Inc A process for preparing hydroxylated compounds cyclopentylpyrimidin
HRP20231100T1 (hr) 2013-11-15 2023-12-22 F. Hoffmann - La Roche Ag Postupci za proizvodnju pirimidinilciklopentan spojeva
KR102284938B1 (ko) * 2013-11-27 2021-08-02 선샤인 레이크 파르마 컴퍼니 리미티드 다이하이드로피리미딘 유도체 및 이의 중간산물의 제조 방법
SG10201806450SA (en) 2014-09-26 2018-09-27 Hoffmann La Roche PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS
CA3175354A1 (en) 2020-06-16 2021-12-23 F. Hoffmann-La Roche Ag Process for making hydroxylated cyclopentylpyrimidine compounds
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2178829A1 (en) 1993-12-12 1995-06-15 Yigal Cohen A novel method to protect plants from fungal infection
EP0973396A4 (en) 1997-04-07 2001-02-07 Merck & Co Inc METHOD FOR TREATING CANCER
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
CA2363169A1 (en) 1999-03-03 2000-09-08 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU766079B2 (en) 1999-06-03 2003-10-09 Teikoku Hormone Mfg. Co., Ltd. Substituted pyrazole compounds
WO2001022963A1 (en) 1999-09-27 2001-04-05 Merck & Co., Inc. Method of preventing osteoporosis
WO2004108673A2 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
US20050130954A1 (en) 2003-11-21 2005-06-16 Mitchell Ian S. AKT protein kinase inhibitors
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
JP5157576B2 (ja) 2007-05-14 2013-03-06 住友化学株式会社 光学活性2−アルキル−1,1,3−トリアルコキシカルボニルプロパンの製造方法
SI2173723T1 (sl) * 2007-07-05 2011-12-30 Array Biopharma Inc Pirimidil ciklopentani kot inhibitorji AKT-protein-kinaze
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
JP5346345B2 (ja) * 2008-01-09 2013-11-20 アレイ バイオファーマ、インコーポレイテッド Aktタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン類
US8748462B2 (en) * 2008-10-15 2014-06-10 Amgen Inc. Spirocyclic GPR40 modulators
EP2419404B1 (en) 2009-04-15 2015-11-04 AbbVie Inc. Anti-viral compounds
AU2010310786B2 (en) 2009-10-23 2014-03-27 Eli Lilly And Company AKT inhibitors
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
DK2861582T3 (en) 2012-05-17 2016-08-22 Array Biopharma Inc A process for preparing hydroxylated compounds cyclopentylpyrimidin
KR102123131B1 (ko) 2012-05-17 2020-06-15 제넨테크, 인크. 하이드록실화 사이클로펜타피리미딘 화합물 및 이의 염의 제조 방법
CN104520263B (zh) 2012-05-17 2016-11-09 基因泰克公司 制备氨基酸化合物的方法
CA2889855A1 (en) 2012-11-01 2014-05-08 Robert S. Katz Methods for treating fibromyalgia
EP2956441A4 (en) 2013-02-18 2016-11-02 Scripps Research Inst MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL
US10131637B2 (en) 2013-03-15 2018-11-20 Shifa Biomedical Corporation Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases

Also Published As

Publication number Publication date
MA37649A1 (fr) 2016-06-30
EP2861583A1 (en) 2015-04-22
AU2013262568A1 (en) 2015-01-22
EP2861583B1 (en) 2016-06-29
JP6214636B2 (ja) 2017-10-18
AU2013262568B2 (en) 2017-08-31
CA2873653A1 (en) 2013-11-21
US9309204B2 (en) 2016-04-12
SI2861583T1 (sl) 2016-10-28
JP2015518837A (ja) 2015-07-06
BR112014028570A2 (pt) 2018-04-24
HK1208673A1 (en) 2016-03-11
CN104487430B (zh) 2016-08-24
US20150099881A1 (en) 2015-04-09
ES2588878T3 (es) 2016-11-07
KR20150020211A (ko) 2015-02-25
SG11201407613RA (en) 2015-01-29
PL2861583T3 (pl) 2016-12-30
DK2861583T3 (en) 2016-10-03
MX2014013865A (es) 2015-05-07
CN104487430A (zh) 2015-04-01
WO2013173736A1 (en) 2013-11-21
RU2014151017A (ru) 2016-07-10
IL235714A0 (en) 2015-02-01

Similar Documents

Publication Publication Date Title
MA37649A1 (fr) Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées
MA37647A1 (fr) Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci
UA111854C2 (uk) Способи і проміжні сполуки для отримання інгібіторів jak
JOP20190230A1 (ar) طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
MY196260A (en) Small Molecule Inhibitors of the Jak Family Of Kinases
MY161416A (en) 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1h-pyrazol-1-yl]octane-or heptane-nitrile as jak inhibitors
MX2016007371A (es) Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados.
MX2011012353A (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
MX2017016772A (es) Metodo para producir un derivado de 7h-pirrolo[2,3-d]pirimidina e intermediario del mismo.
ATE474835T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
WO2010147898A3 (en) Small molecule inhibitors of spleen tyrosine kinase (syk)
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
AU2016320892A8 (en) Salts of a Pim kinase inhibitor
MA37751A1 (fr) Procédé de préparation de composés d'acides aminés
NZ586720A (en) Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
MX2010006331A (es) Hidantoinas sustituidas como inhibidores de cinasa mek.
IN2013MU02611A (enExample)
MA50430B1 (fr) Composés d'imidazo[4,5-d]pyrrolo[2,3-b]pyridine comme inhibiteurs de janus kinases
UY30666A1 (es) Trizoles biciclicos como moduladores de proteinquinasas